| Literature DB >> 20056589 |
Chensheng Lu1, Christina M Holbrook, Leo M Andres.
Abstract
BACKGROUND: A physiologically based pharmacokinetic (PBPK) model would make it possible to simulate the dynamics of chemical absorption, distribution, metabolism, and elimination (ADME) from different routes of exposures and, in theory, could be used to evaluate associations between exposures and biomarker measurements in blood or urine.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20056589 PMCID: PMC2831956 DOI: 10.1289/ehp.0901144
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
PBPK model parameters that describe physiologic TCPY in rats and adult humans.
| Rat | Adult human | |
|---|---|---|
| Partition coefficients for TCPY | ||
| Brain:blood | 23.027 | 15.89 |
| Fat:blood | 124.46 | 91.562 |
| Kidney:blood | 8.809 | 6.05 |
| Liver:blood | 9.648 | 9.95 |
| Rapidly perfused:blood | 7.452 | 3.94 |
| Slowly perfused:blood | 5.445 | 7.47 |
| Partition coefficients for TCPY-g | ||
| Brain:blood | 1.439 | 1.54 |
| Fat:blood | 6.14 | 0.221 |
| Kidney:blood | 1.103 | 1.16 |
| Liver:blood | 1.046 | 1.27 |
| Rapidly perfused:blood | 1.071 | 1.05 |
| Slowly perfused:blood | 1 | 1.13 |
| Glucuronidation rate | ||
| | 10 | 10 |
| | 1 | 1 |
| Saturable elimination | ||
| | 10 | 0.74 |
| KURN4 (mmol/L) | 10 | 10 |
| Parameters scaled by BW | ||
| Liver | ||
| CPF to CPF-ox | 0.08 | 0.08 |
| CPF to TCPY | 0.273 | 0.273 |
| CPF-ox to TCPY | 74.4 | 74.4 |
| Blood | ||
| CPF-ox to TCPY | 57 | 57 |
| GI absorption rate constant (per hr) | ||
| Stomach to portal blood | 0.01 | 0.01 |
| Stomach to intestine | 0.5 | 0.5 |
| Intestine to portal blood | 0.5 | 0.1 |
| Intestine to feces | 0 | 0.4 |
Values from Timchalk et al. (2002).
Values from Nolan et al. (1984).
Physiologic parameters used in the child-specific PBPK model.
| Participant ID | Age (years) | BW (kg) | Normalized cardiac output (L/H) | Normalized alveolar ventilation rate (L/H) |
|---|---|---|---|---|
| R1 | 4 | 15.5 | 23.94 | 14.24 |
| R2 | 4 | 21.4 | 18.8 | 11.18 |
| R3 | 4 | 14.5 | 25.17 | 14.98 |
| R4 | 5 | 16.8 | 26.17 | 15.56 |
| R5 | 3 | 13.4 | 22.1 | 13.34 |
| R6 | 5 | 19.6 | 23.31 | 13.86 |
| S1 | 4 | 17.3 | 22.04 | 14.3 |
| S2 | 6 | 18.2 | 27.83 | 16.68 |
| S3 | 3 | 15 | 20.31 | 12.25 |
| S4 | 4 | 15.5 | 23.94 | 14.98 |
| S5 | 5 | 16.8 | 26.17 | 15.56 |
| S6 | 6 | 22.7 | 23.58 | 14.14 |
| S7 | 3 | 14.5 | 20.83 | 12.57 |
Age rounded up to a whole year.
Equations in Price et al. (2003) were used to calculate rates of cardiac output and alveolar ventilation; results were divided by BW3/4.
Study participant did not provide a BW; value taken from Exposure Factors Handbook, Table 11–3 (U.S. EPA 2002b).
Figure 1Sampling schedule for the 1998 study (1) and the corresponding PBPK model simulation (2). Abbreviations: A, 24-hr indoor air; F, 24-hr duplicate diets; HD, house dust; S, soil; W, hand/toy wipe; U, spot urine. The arrow indicates a 24-hr sampling.
Modeled exposure duration for 168 hr; however, figure truncated after the 60th hr. Exposure scenario included rate ingestion and inhalation. Exposure scenario included rate ingestion, inhalation, and bolus food ingestion.
Figure 2Pharmacokinetic curves for TCPY (mmol) in urine following an oral dose of 0.5 mg/kg and dermal application of 5 mg/kg in humans. The lines are the PBPK model simulations compared with the oral data from Nolan et al. 1984 (square) and Timchalk et al. 2002a (diamond) and to the dermal data from Nolan et al. 1984 (triangle).
Exposure data collected from 13 children 2–6 years of age in 1998 and their predicted and measured 24-hr cumulative TCPY excretions (μmol/day).
| Participant ID | Sampling season | Toy (μg/sample) | Soil (μg/g) | Indoor air (μmol/m3) | House dust (μg/g) | Food (μg/day) | 24-hr cumulative TCPY excretion | ||
|---|---|---|---|---|---|---|---|---|---|
| Predicted | Measured | Ratio | |||||||
| R1 | 1 | NA | 0.025 | 0.01 | 0.28 | 0 | 3.6 × 10−5 | 1.6 × 10−2 | 2.2 × 10−3 |
| 2 | 0 | 0 | 0 | 0.28 | 0 | 3.3 × 10−5 | 2.7 × 10−2 | 1.2 × 10−3 | |
| R2 | 1 | NA | 0 | 0.001 | 0.28 | 0 | 3.0 × 10−5 | 6.7 × 10−3 | 4.5 × 10−3 |
| 2 | 0 | 0 | 0.001 | 0.28 | 0 | 3.0 × 10−5 | 5.2 × 10−3 | 5.9 × 10−3 | |
| R3 | 1 | 0 | 0 | 0 | 0.28 | 0 | 3.3 × 10−5 | 2.5 × 10−4 | 1.4 × 10−1 |
| 2 | 0.12 | 0 | 0.001 | 0.28 | 0 | 1.0 × 10−4 | 2.0 × 10−2 | 5.0 × 10−3 | |
| R4 | 1 | NA | 0 | 0.003 | 0.28 | 0 | 3.2 × 10−5 | 1.6 × 10−2 | 2.0 × 10−3 |
| 2 | 0 | 0 | 0.003 | 0.28 | 0 | 3.2 × 10−5 | 1.1 × 10−2 | 2.9 × 10−3 | |
| R5 | 1 | NA | 0 | 0.001 | 0.28 | 0 | 3.4 × 10−5 | 1.9 × 10−3 | 1.8 × 10−2 |
| 2 | 0.15 | 0 | 0.003 | 0.28 | 0 | 1.4 × 10−4 | 5.3 × 10−3 | 2.7 × 10−2 | |
| R6 | 1 | NA | 0.025 | 0.002 | 0.28 | 0 | 3.4 × 10−5 | 6.5 × 10−3 | 5.2 × 10−3 |
| 2 | 0.15 | 0 | 0.003 | 0.28 | 0 | 4.9 × 10−5 | 2.5 × 10−3 | 2.0 × 10−2 | |
| S1 | 1 | NA | 0 | 0.002 | 0.28 | 0 | 3.2 × 10−5 | 0 | N.A |
| 2 | 0 | 0 | 0.002 | 0 | 39.83 | 4.7 × 10−2 | 6.3 × 10−2 | 0.74 | |
| S2 | 1 | NA | 0.025 | 0.001 | 0 | 0 | 2.8 × 10−6 | 5.8 × 10−3 | 4.9 × 10−4 |
| 2 | 0 | 0 | 0.001 | 0.28 | 0 | 3.2 × 10−5 | 1.7 × 10−2 | 1.9 × 10−3 | |
| S3 | 1 | NA | 0 | 0.004 | 0 | 0 | 9.4 × 10−8 | 3.0 × 10−2 | 3.1 × 10−6 |
| 2 | 0 | 0 | 0.002 | 0.28 | 0 | 3.3 × 10−5 | 3.7 × 10−2 | 9.0 × 10−4 | |
| S4 | 1 | NA | 0 | 0.001 | 0 | 0 | 2.4 × 10−8 | 2.8 × 10−2 | 8.5 × 10−7 |
| 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1.2 × 10−2 | 0 | |
| S5 | 1 | NA | 0.025 | 0.005 | 0.28 | 0 | 3.5 × 10−5 | 5.2 × 10−3 | 6.8 × 10−3 |
| 2 | 0 | 0 | 0.003 | 0 | 0 | 8.7 × 10−8 | 1.1 × 10−2 | 8.1 × 10−6 | |
| S6 | 1 | NA | 0 | 0.001 | 0 | 2.63 | 1.1 × 10−2 | 1.5 × 10−2 | 0.75 |
| 2 | 0.05 | 0 | 0.001 | 0 | 0 | 1.7 × 10−5 | 1.8 × 10−2 | 9.3 × 10−4 | |
| S7 | 1 | NA | 0 | 0.001 | 0 | 0 | 1.9 × 10−8 | 1.2 × 10−2 | 1.7 × 10−6 |
| 2 | 0.05 | 0 | 0.001 | 0.28 | 0 | 5.2 × 10−5 | 2.2 × 10−2 | 2.4 × 10−3 | |
NA, not applicable.
Sampling season: 1, summer; 2, fall.
Figure 3The cumulative excretion difference of TCPY between measured urinary biomarker data and PBPK-predicted values for two study participants. (A) Participant S1-2 (Table 3) whose PBPK input included inhalation (indoor air) and single bolus ingestion (food intake). (B) Participant S6-1 (Table 3) whose PBPK input included inhalation (indoor air) and single bolus ingestion (food intake).
Descriptive statistics for measured, adjusted measured, and predicted daily dose (μg/kg/day) of CPF for 13 children 2–5 years of age, summer and fall,1998.
| Daily dose, summer 1998 | Daily dose, fall 1998 | |||
|---|---|---|---|---|
| Participant ID | Calculated | Predicted | Calculated | Predicted |
| R1 | 0.37 | 0.004 | 0.58 | 0.004 |
| R2 | 0.11 | 0.003 | 0.08 | 0.003 |
| R3 | 0.01 | 0.004 | 0.49 | 0.012 |
| R4 | 0.33 | 0.003 | 0.23 | 0.003 |
| R5 | 0.05 | 0.004 | 0.14 | 0.018 |
| R6 | 0.12 | 0.003 | 0.04 | 0.005 |
| S1 | 0 | 0.003 | 1.32 | 2.302 |
| S2 | 0.11 | < 0.001 | 0.33 | 0.003 |
| S3 | 0.7 | < 0.001 | 0.86 | 0.004 |
| S4 | 0.64 | < 0.001 | 0.38 | < 0.001 |
| S5 | 0.11 | 0.004 | 0.22 | < 0.001 |
| S6 | 0.23 | 0.440 | 0.28 | 0.001 |
| S7 | 0.28 | < 0.001 | 0.54 | 0.006 |
| Descriptive statistics | ||||
| Mean | 0.24 | 0.04 | 0.42 | 0.18 |
| SD | 0.23 | 0.12 | 0.35 | 0.66 |
| Percentile | ||||
| 5 | < 0.0001 | < 0.0001 | 0.04 | < 0.0001 |
| 25 | 0.08 | 0.0001 | 0.18 | 0.0001 |
| 50 | 0.12 | 0.003 | 0.33 | 0.004 |
| 75 | 0.35 | 0.004 | 0.56 | 0.009 |
| 90 | 0.68 | 0.27 | 1.14 | 1.39 |
Calculated daily dose using the mass balance equations and the measured 24-hr cumulative urinary TCPY excretion.
Output from the PBPK/ERDEM simulation.